Giovanni Brandi, Andrea Palloni, Alessio Giuseppe Morganti, Should we incorporate ablative radiotherapy in standard treatment of advanced intrahepatic cholangiocarcinoma?, «TRANSLATIONAL CANCER RESEARCH», 2016, 5, pp. S450 - S453 [Scientific article]
Mosconi, Cristina; Gramenzi, Annagiulia; Ascanio, Salvatore; Cappelli, Alberta; Renzulli, Matteo; Pettinato, Cinzia; Brandi, Giovanni; Monari, Fabio; Cucchetti, Alessandro; Trevisani, Franco; Golfieri, Rita, Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study, «BRITISH JOURNAL OF CANCER», 2016, 115, pp. 297 - 302 [Scientific article]Open Access
Brandi, Giovanni; De Lorenzo, Stefania; Corbelli, Jody, Adjuvant Treatment and Follow-up Strategies, in: Cholangiocarcinoma, New York, Nova Science Publishers, Inc., 2015, pp. 476 - 496 [Chapter or essay]
Tavolari, Simona; Venturi, Michela; Brandi, Giovanni, Carcinogenesis of Cholangiocarcinoma, in: Cholangiocarcinoma, New York, Nova Science Publisher, Inc., 2015, pp. 65 - 80 [Chapter or essay]
Brandi, Giovanni; Frega, Giorgio; Barbera, Maria Aurelia; Palloni, Andrea, Chemotherapy in Patients with Advanced Cholangiocarcinoma, in: Cholangiocarcinoma, New York, Nova Science Publishers, Inc, 2015, pp. 429 - 450 [Chapter or essay]
Brandi, Giovanni; Ercolani, Giorgio, Cholangiocarcinoma, New York, Nova Science Publisher, Inc., 2015, pp. 531 . [Research monograph]
Brandi, Giovanni; Venturi, Michela; Ercolani, Giorgio, Diagnostic and Therapeutic Algorithms for Cholangiocarcinoma, in: Cholangiocarcinoma, New York, Nova Science Publishers, Inc, 2015, pp. 509 - 520 [Chapter or essay]
Vasuri, Francesco; Rocchi, Laura; Degiovanni, Alessio; Giunchi, Francesca; Brandi, Giovanni; Treré, Davide; Montanaro, Lorenzo; D'Errico-Grigioni, Antonia, Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: Correlations with cholangiocarcinoma aggressiveness, «HISTOPATHOLOGY», 2015, 66, pp. 244 - 251 [Scientific article]
Minichillo, Santino; Pantaleo, Maria Abbondanza; Nannini, Margherita; Coccolo, Fabio; Gatto, Lidia; Biasco, Guido; Brandi, Giovanni, Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma, «BMC RESEARCH NOTES», 2015, 8, Article number: 325 , pp. 1 - 4 [Scientific article]Open Access
Brandi, Giovanni, Follow-up in oncologia, Bologna, Bononia, 2015, pp. 368 . [Research monograph]
Brandi, Giovanni; DE LORENZO, Stefania; DI GIROLAMO, Stefania; Bellentani, S; Saccoccio, G; Biasco, Guido, Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib., «TUMORI», 2015, 101(2), pp. 46 - 48 [Scientific article]
Brandi, Giovanni; Farioli, Andrea; Astolfi, Annalisa; Biasco, Guido; Tavolari, Simona, Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies, «ONCOTARGET», 2015, 6, pp. 14744 - 14753 [Scientific article]Open Access
I. Garajová; G. Brandi; G. Biasco; [..]; E. Giovannetti, L27MiR-21 expression as prognostic biomarker in extrahepatic but not intrahepatic radically resected cholangiocarcinomas, in: Annals of Oncology, 2015(atti di: x, x, x) [Poster]
Saponara, Maristella; Urbini, Milena; Astolfi, Annalisa; Indio, Valentina; Ercolani, Giorgio; Del Gaudio, Massimo; Santini, Donatella; Pirini, Maria Giulia; Fiorentino, Michelangelo; Nannini, Margherita; Lolli, Cristian; Mandrioli, Anna; Gatto, Lidia; Brandi, Giovanni; Biasco, Guido; Pinna, Antonio Daniele; Pantaleo, Maria Abbondanza, Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS), «ONCOTARGET», 2015, 6, pp. 42243 - 42257 [Scientific article]
Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M; REACH Trial Investigators; Brandi G., Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial, «THE LANCET ONCOLOGY», 2015, 16, pp. 859 - 870 [Scientific article]
